Med Tech-related technology assessments from NICE in March 2025

The National Institute for Health and Care Excellence (NICE) develops Interventional Procedures Guidance (IPG) for most novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

In March 2025, NICE published one new IPG on Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension and recommended the procedure only as a part of a formal research study approved by the NHS Research Ethics Committee. Further research is required to investigate patient selection, the variety and quantity of antihypertensive medications utilized, and adherence to these medications. Additionally, it is important to assess the impact of optimizing antihypertensive treatments and other factors, including lifestyle changes, on blood pressure levels, the longevity of their effects, quality of life (both qualitative and quantitative outcomes), and potential complications. NICE has determined that the evidence regarding the safety of the procedure is limited, and there is uncertainty surrounding its effectiveness in reducing blood pressure and the duration of any resulting changes, particularly due to the significant placebo effect observed.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.